ポスト

1/2 Following the DANGER SHOCK trial demonstrating reduced mortality with Impella in cardiogenic shock, the independent DSMB of the RECOVER IV trial has strongly recommended the trial be discontinued because of lack of equipoise. Therefore, we are ceasing enrollment in the trial.

メニューを開く

Gregg W. Stone MD@GreggWStone

人気ポスト

もっと見る
Yahoo!リアルタイム検索アプリ